Cystatin C as a marker of chronic kidney desease


DOI: https://dx.doi.org/10.18565/therapy.2019.4.57-62

Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A.

1) I.K. Akhunbayev Kyrgyz State Medical Academy, Bishkek; 2) The First President of Russia B.N. Yeltsin Kyrgyz Russian Slavic University, Bishkek, Kyrgyzstan; 3) Scientific Research Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan; 4) I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia; 5) Family Medicine Center №7, Bishkek, Kyrgyzstan
The purpose: to study of the prevalence of reduced glomerular filtration rate (GFR) in the Kyrgyz Republic are presented.
Material and methods. Analysis of the prevalence of reduced GFR on the basis of an assessment of the content of cystatin C blood serum were conducted in 1121 patients of therapeutic profile.
Results and conclusion. It was found that the prevalence of small and the moderate decline in GFR in the Kyrgyz Republic is 47.0% and 17.9%, respectively. At the same time, the prevalence of reduced GFR in men, he was taller than a woman. A closer and statistically significant relationship were recorded between the content of cystatin C in blood serum and the magnitude of GFR in patients with C1-C4 gradations of renal dysfunction. Data on high prevalence of comorbid pathology, hypertension and coronary artery disease heart disease in C3, C4 and C5 gradations of renal dysfunction in representative sample of the Kyrgyz Republic.
Keywords: glomerular load, comorbid pathology, cystatin C, arterial hypertension, chronic kidney disease
Read entire article

Literature


  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39(Suppl. 1): 1–266. doi: https://doi.org/CliCa0405689692.

  2. Кобалава Ж.Д., Виллевальде С.В., Моисеев В.С. Сердечно-сосудистые заболевания и функциональное состояние почек. Российский кардиологический журнал. 2013; 4: 33–37. doi: https://doi.org/10.15829/1560-4071-2013-4-33-37.

  3. Clase C.M., Garg A.X., Kiberd B.A. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 2002; 13(5): 1338–49.

  4. Hasan M., Sutradhar I., Gupta R.D., Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrology. 2018; 19: 291. doi: https://doi.org/10.1186/s12882-018-1072-5.

  5. Hodel N.C., Hamad A., Praehauser C., Mwangoka G., Kasella I.M. et al. The epidemiology of chronic kidney disease and the association with non-communicable and communicable disorders in a population of sub-Saharan Africa. PloSone. 2018; 13(10): С.e0205326. doi: https://doi.org/10.1371/journal.pone.0205326.

  6. Chukwuonye I.I., Ogah O.S., Anyabolu E.N., Ohagwu K.A., Nwabuko O.C. et al. Prevalence of chronic kidney disease in Nigeria: systematic review of population-based studies. Int. J. Nephrol. Renovasc. Dis. 2018; 22(11): 165–72. doi: https://doi.org/10.2147/IJNRD.S162230.

  7. Piccolli A.P., Nascimento M.M., Riella M.C. Prevalence of chronic kidney disease in a population in southern Brazil (Pro-Renal Study). Braz. J. Nephrol. 2017; 39(4): 384–90. doi: http://dx.doi.org/10.5935/0101-2800.20170070.

  8. Кобалава Ж.Д., Виллевальде С.В., Багманова Н.Х., Батюшин М.М., Орлова Г.М. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией в зависимости от наличия сахарного диабета: результаты эпидемиологического исследования хронограф. Российский кардиологический журнал. 2018; 2: 91–101. doi.https://doi.org/10.15829/1560-4071-2018-2-91-101

  9. Васильева М.П., Руденко Т.Е., Кутырина И.М., Соломахина Н.И. Цистатин С-новый маркер гипертрофии миокарда левого желудочка у пациентов с хронической болезнью почек. Терапевтический архив. 2015; 87(6): 17–22. doi: 10.17116/terarkh201587617-22

  10. Peralta C.A., Katz R., Sarnak M.J., Ix J., Fried L.F. et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J. Am. Soc. Nephrol. 2011; 22(1): 147–55. doi: https://doi.org/10.1681/ASN.2010050483.

  11. Муркамилов И.Т., Айтбаев К.А., Фомин В.В., Муркамилова Ж.А., Сабиров И.С. Содержание цистатина С плазмы крови и его взаимосвязь с аугментационным индексом и центральным артериальным давлением у пациентов терапевтического профиля. Клиническая нефрология. 2018; 3: 31–40. doi:10.18565/nephrology.20183.31–40

  12. Муркамилов И.Т., Сабиров И.С., Фомин В.В., Муркамилова Ж.А. Изучение возможностей использования расчетных методов оценки скорости клубочковой фильтрации в зависимости от нозологического типа социально-значимых заболеваний. Клиническая нефрология. 2019; 1: 32–41. doi: https://dx.doi.org/10.18565/nephrology

  13. Hoek F.J., Kemperman F.A., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular fi ltration rate. Nephrol. Dial. Transplant. 2003; 18(10): 2024–31. doi:10.1093/ndt/gfg349

  14. Paini A., Salvetti M., Caligaris S., Castelli F., Muiesan M. L. Chronic kidney disease in low-middle income populations: a call to action for screening and prevention. Intern. Emerg. Med. 2019; 14(2): 199–202. doi: https://doi.org/10.1007/s11739-018-2005-9

  15. Abrahamson M., Olafsson I., Palsdottir A., Ulvsbäck M., Lundwall Å. et al. Structure and expression of the human cystatin C gene. Biochem. J. 1990; 268(2): 287–94. doi: 10.1042/bj2680287.

  16. Herget-Rosenthal S., Marggraf G., Hüsing J., Göring F., Pietruck F. et al. Early detection of acute renal failure by serum cystatin C. Kidney Internat. 2004; 66(3): 1115–22. doi: https://doi.org/10.1111/j.1523-1755.2004.00861.x

  17. Kyhse-Andersen J., Schmidt C., Nordin G., Andersson B., Nilsson-Ehle P. et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 1994; 40(10): 1921–26.

  18. Wong C.W., Teo B.W., Lamoureux E., Ikram M.K., Wang J.J. et al. Serum cystatin C, markers of chronic kidney disease, and retinopathy in persons with diabetes. J. Diabet. Res. 2015; 2015: 1–8. doi: http://dx.doi.org/10.1155/2015/404280

  19. Luis-Lima S., Escamilla-Cabrera B., Negrín-Mena N., Estupiñán S., Delgado-Mallén P. et al. Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. Nephrol. Dial. Transplant. 2018; 34(2): 287–94. doi: https://doi.org/10.1093/ndt/gfy086

  20. Agarwal R., Delanaye P. Glomerular filtration rate: when to measure and in which patients? Nephrol. Dialys. Transplant. 2018. doi: https://doi.org/10.1093/ndt/gfy363.

  21. Perico L., Perico N., Benigni A. The incessant search for renal biomarkers: is it really justified? Curr. Opin. Nephrol. Hypertens. 2019; 28(2): 195–202. doi: 10.1097/MNH.0000000000000481.

  22. Bukabau J.B., Yayo E., Gnionsahé A., Monnet D., Pottel H. et al. Performance of creatinine-or cystatin C - based equations to estimate glomerular filtration rate in sub-Saharan African populations. Kidney Internat. 2019. doi: https://doi.org/10.1016/j.kint.2018.11.045.

  23. Kervella D., Lemoine S., Sens F., Dubourg L., Sebbag L. et al. Cystatin C Versus Creatinine for GFR Estimation in CKD Due to Heart Failure. Am. J. Kidney Dis. 2017; 69(2): 321–23. doi: https://doi.org/10.1053/j.ajkd.2016.09.016.

  24. Stevens L.A., Stevens L.A., Li S., Wang C., Huang C. et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am. J. Kidney Dis. 2010; 55(3): 23–33. doi:https://doi.org/10.1053/j.ajkd.2009.09.035.


About the Autors

Ilkhom T. Murkamilov, PhD, nephrologist, acting associate professor of the Department of faculty therapy of I.K. Akhunbayev Kyrgyz State Medical Academy, The First President of Russia B.N. Yeltsin Kyrgyz Russian Slavic University. Address: Kyrgyzstan, Bishkek, 92 I.K. Akhunbayev str. E-mail: murkamilov.i@mail.ru. ORCID: org/0000-0001-8513-9279
Kubanych A. Aitbaev, MD, professor, the Head of laboratory of pathophysiology of Research Institute of molecular biology and medicine at the National Center of cardiology and therapy of the Ministry of Kyrgyzstan. Address: Kyrgyzstan, Bishkek, 3 Togolok Moldo str.
Viktor V. Fomin, MD, professor, corresponding member of RAS, the Head of Department of faculty therapy No 1 of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia. Address: 119146, Moscow, 6 Bolshaya Pirogovskaya str. Тел.: +7 (499) 248-62-22. E-mail: fomin@mma.ru. Scopus Author ID: 34769949900
Zhamila A. Murkamilova, therapist of Family medicine Center No 7. Address: Kyrgyzstan, Bishkek, 3/1 Togolok Moldo str. ORCID: org/0000-0002-7653-0433


Similar Articles

Back to Content

Бионика Медиа